Maze Therapeutics
Clinical trials sponsored by Maze Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for APOL1 kidney disease: targeted drug enters Mid-Stage trial Results expected Sep 2026 (estimated)
-
New oral drug aims to tame PKU's toxic protein buildup
Disease control Recruiting nowThis study tests an experimental oral drug called MZE782 in adults with phenylketonuria (PKU), a genetic disorder that prevents the body from breaking down an amino acid called phenylalanine (Phe). High Phe levels can cause brain damage. The trial compares two doses of MZE782 aga…
Phase 2 • Sponsor: Maze Therapeutics • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for APOL1 kidney disease: targeted drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called MZE829 in 56 adults with chronic kidney disease caused by a specific genetic risk (APOL1). The goal is to see if the drug can safely reduce protein leakage into urine, a sign of kidney damage. Participants will take the drug for 12 wee…
Phase 2 • Sponsor: Maze Therapeutics • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC